← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. Financial Ratios

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. XRAY
  3. Financial Ratios
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

DENTSPLY SIRONA Inc. (XRAY) Financial Ratios

30 years of historical data (1996–2025) · Healthcare · Medical - Instruments & Supplies

View Quarterly Ratios →

P/E Ratio
-3.65
↓-112% vs avg
5yr avg: 29.83
00%ile100
30Y Low14.1·High95.9
View P/E History →
EV/EBITDA
↓
7.18
↓-64% vs avg
5yr avg: 19.70
00%ile100
30Y Low7.3·High40.8
P/FCF
↓
21.11
-5% vs avg
5yr avg: 22.25
054%ile100
30Y Low13.7·High33.5
P/B Ratio
↓
1.63
↓-20% vs avg
5yr avg: 2.05
07%ile100
30Y Low1.6·High4.6
ROE
↓
-36.4%
↑-107% vs avg
5yr avg: -17.6%
03%ile100
30Y Low-36%·High21%
Debt/EBITDA
↑
4.09
↓-20% vs avg
5yr avg: 5.13
088%ile100
30Y Low0.5·High8.9

Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.

XRAY Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

DENTSPLY SIRONA Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 21.1x P/FCF, 5% below the 5-year average of 22.2x.

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$2.2B$2.3B$3.9B$7.5B$6.9B$12.3B$11.5B$12.7B$8.3B$15.1B$12.8B
Enterprise Value$4.3B$4.4B$5.9B$9.5B$8.6B$14.2B$13.5B$13.9B$9.7B$16.4B$13.9B
P/E Ratio →-3.65————29.83—48.37——29.76
P/S Ratio0.600.621.021.901.752.903.443.162.093.783.42
P/B Ratio1.631.701.982.291.802.462.332.491.632.271.57
P/FCF21.1121.9113.7333.0918.6523.8520.4224.9026.7733.4929.25
P/OCF9.349.708.3720.0113.2718.7017.6820.0716.7025.0922.71

P/E links to full P/E history page with 30-year chart

XRAY EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

DENTSPLY SIRONA Inc.'s enterprise value stands at 7.2x EBITDA, 64% below its 5-year average of 19.7x. The Healthcare sector median is 14.4x, placing the stock at a 50% discount on an enterprise-value basis.

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—1.201.542.402.203.374.043.452.434.103.72
EV / EBITDA7.187.32—36.86—14.9340.7720.55——19.16
EV / EBIT17.21————23.50—38.06——29.19
EV / FCF—42.5120.8441.7123.4927.6524.0127.2531.0936.3531.83

XRAY Profitability

Margins and return-on-capital ratios measuring operating efficiency

DENTSPLY SIRONA Inc. earns an operating margin of 6.8%. Operating margins have expanded from -2.1% to 6.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -36.4% indicates the company is currently destroying shareholder equity. ROIC of 5.1% represents adequate returns on invested capital.

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin50.0%50.0%51.6%52.6%54.2%55.5%49.6%53.8%51.9%54.8%53.4%
Operating Margin6.8%6.8%-23.2%-2.1%-23.9%14.4%-0.1%8.8%-24.0%-39.7%12.1%
Net Profit Margin-16.3%-16.3%-24.0%-3.3%-24.2%9.7%-2.2%6.4%-25.4%-38.8%11.5%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-36.4%-36.4%-34.8%-3.7%-21.6%8.3%-1.5%5.0%-17.2%-21.0%8.2%
ROA-10.7%-10.7%-13.9%-1.8%-11.3%4.4%-0.8%3.0%-10.6%-14.1%5.4%
ROIC5.1%5.1%-14.3%-1.2%-11.2%6.6%-0.0%4.1%-10.0%-13.8%5.5%
ROCE6.1%6.1%-17.4%-1.4%-13.0%7.6%-0.0%4.6%-11.2%-15.6%6.1%

XRAY Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

DENTSPLY SIRONA Inc. carries a Debt/EBITDA ratio of 4.1x, which is highly leveraged (24% above the sector average of 3.3x). Net debt stands at $2.1B ($2.5B total debt minus $326M cash).

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity1.841.841.170.700.560.460.500.310.320.240.19
Debt / EBITDA4.094.09—8.91—2.407.422.37——2.08
Net Debt / Equity—1.601.030.600.470.390.410.230.260.190.14
Net Debt / EBITDA3.553.55—7.62—2.056.091.77——1.55
Debt / FCF—20.607.128.624.843.803.592.344.322.862.58
Interest Coverage-4.52-4.52-12.57-1.16-15.239.93-0.0612.41-24.69-40.9313.28

XRAY Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

A current ratio of 1.51x means DENTSPLY SIRONA Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 1.03x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.38x to 1.51x over the past 3 years.

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.511.511.101.381.621.471.312.011.862.122.44
Quick Ratio1.031.030.740.951.081.060.961.451.271.461.77
Cash Ratio0.240.240.170.230.310.270.320.410.310.340.50
Asset Turnover—0.680.660.540.510.460.360.470.460.380.32
Inventory Turnover2.872.873.253.012.863.663.543.313.202.903.37
Days Sales Outstanding—68.2458.3269.5963.7569.2777.1875.1464.2768.2061.98

XRAY Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

DENTSPLY SIRONA Inc. returns 5.9% to shareholders annually primarily through dividends.

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield5.9%5.6%3.3%1.5%1.5%0.7%0.8%0.6%0.9%0.5%0.5%
Payout Ratio—————22.4%—31.6%——15.0%

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield—————3.4%—2.1%——3.4%
FCF Yield4.7%4.6%7.3%3.0%5.4%4.2%4.9%4.0%3.7%3.0%3.4%
Buyback Yield0.0%0.0%6.5%4.0%2.2%1.6%2.0%2.0%3.0%2.7%6.4%
Total Shareholder Yield5.9%5.6%9.7%5.5%3.7%2.4%2.8%2.7%3.9%3.2%6.9%
Shares Outstanding—$199M$203M$212M$216M$220M$219M$224M$224M$229M$222M

Peer Comparison

Compare XRAY with 10 similar companies in its peer group

CompanyMarket CapP/EEV/EBITDAP/FCFGross MarginOp MarginROEROICDebt/EBITDA
XRAY logoXRAYYou$2B-3.77.221.150.0%6.8%-36.4%5.1%4.1
ALGN logoALGN$12B29.813.924.668.3%15.3%10.4%15.4%0.1
HSIC logoHSIC$8B21.610.914.129.1%5.7%8.3%7.1%3.4
NVST logoNVST$4B86.713.317.555.0%8.3%1.6%4.8%5.0
MMSI logoMMSI$4B29.313.117.248.7%12.2%8.7%7.2%2.8
HOLX logoHOLX$17B30.517.418.461.0%17.4%11.1%9.4%2.6
CNMD logoCNMD$1B25.210.27.852.8%10.3%4.7%5.8%4.3
ATRC logoATRC$1B-115.877.729.274.4%-0.6%-2.4%-0.6%5.2
SYK logoSYK$113B35.020.326.364.0%19.5%15.1%11.4%2.4
ZBH logoZBH$16B23.59.511.161.6%16.5%5.6%5.4%3.1
IDXX logoIDXX$45B43.731.643.161.8%31.6%66.2%42.5%0.7
Healthcare Median—22.314.418.563.9%-5.2%-33.7%-11.2%3.3

Peer selection based on competitive and market overlap. Compare multiple stocks →

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

See XRAY's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is XRAY Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare XRAY vs ALGN

Side-by-side business, growth, and profitability comparison vs Align Technology, Inc..

Start Comparison

XRAY — Frequently Asked Questions

Quick answers to the most common questions about buying XRAY stock.

What is DENTSPLY SIRONA Inc.'s P/E ratio?

DENTSPLY SIRONA Inc.'s current P/E ratio is -3.7x. The historical average is 26.9x.

What is DENTSPLY SIRONA Inc.'s EV/EBITDA?

DENTSPLY SIRONA Inc.'s current EV/EBITDA is 7.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 16.3x.

What is DENTSPLY SIRONA Inc.'s ROE?

DENTSPLY SIRONA Inc.'s return on equity (ROE) is -36.4%. The historical average is 6.8%.

Is XRAY stock overvalued?

Based on historical data, DENTSPLY SIRONA Inc. is trading at a P/E of -3.7x. Compare with industry peers and growth rates for a complete picture.

What is DENTSPLY SIRONA Inc.'s dividend yield?

DENTSPLY SIRONA Inc.'s current dividend yield is 5.86%.

What are DENTSPLY SIRONA Inc.'s profit margins?

DENTSPLY SIRONA Inc. has 50.0% gross margin and 6.8% operating margin.

How much debt does DENTSPLY SIRONA Inc. have?

DENTSPLY SIRONA Inc.'s Debt/EBITDA ratio is 4.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.